Cozad Asset Management Inc. Purchases 157 Shares of Becton Dickinson and Co (NYSE:BDX)

Share on StockTwits

Cozad Asset Management Inc. grew its position in shares of Becton Dickinson and Co (NYSE:BDX) by 6.3% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 2,666 shares of the medical instruments supplier’s stock after acquiring an additional 157 shares during the quarter. Cozad Asset Management Inc.’s holdings in Becton Dickinson and were worth $674,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. TRUE Private Wealth Advisors bought a new stake in Becton Dickinson and during the second quarter worth $25,000. Allworth Financial LP grew its holdings in Becton Dickinson and by 386.4% during the third quarter. Allworth Financial LP now owns 107 shares of the medical instruments supplier’s stock worth $27,000 after buying an additional 85 shares in the last quarter. Northwest Investment Counselors LLC bought a new stake in Becton Dickinson and during the third quarter worth $27,000. Hexavest Inc. bought a new stake in Becton Dickinson and during the second quarter worth $28,000. Finally, Lipe & Dalton bought a new stake in Becton Dickinson and during the second quarter worth $28,000. Hedge funds and other institutional investors own 84.29% of the company’s stock.

BDX stock opened at $260.70 on Tuesday. The stock’s fifty day simple moving average is $252.83 and its two-hundred day simple moving average is $246.49. The company has a current ratio of 1.09, a quick ratio of 0.67 and a debt-to-equity ratio of 0.84. Becton Dickinson and Co has a 1-year low of $208.62 and a 1-year high of $264.74. The stock has a market cap of $69.69 billion, a P/E ratio of 23.68, a P/E/G ratio of 1.65 and a beta of 1.09.

Becton Dickinson and (NYSE:BDX) last posted its quarterly earnings data on Tuesday, August 6th. The medical instruments supplier reported $3.08 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $3.05 by $0.03. Becton Dickinson and had a return on equity of 14.78% and a net margin of 5.02%. The business had revenue of $4.35 billion for the quarter, compared to analysts’ expectations of $4.37 billion. During the same quarter in the previous year, the firm earned $2.91 earnings per share. The business’s revenue was up 1.7% on a year-over-year basis. As a group, analysts forecast that Becton Dickinson and Co will post 11.68 earnings per share for the current fiscal year.

In other Becton Dickinson and news, SVP Charles R. Bodner sold 1,514 shares of the business’s stock in a transaction on Friday, September 6th. The stock was sold at an average price of $260.08, for a total value of $393,761.12. Following the transaction, the senior vice president now owns 5,180 shares of the company’s stock, valued at $1,347,214.40. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, CEO Vincent A. Forlenza sold 11,532 shares of the business’s stock in a transaction on Friday, September 6th. The stock was sold at an average price of $260.38, for a total value of $3,002,702.16. Following the completion of the transaction, the chief executive officer now directly owns 218,671 shares in the company, valued at approximately $56,937,554.98. The disclosure for this sale can be found here. In the last three months, insiders sold 37,249 shares of company stock worth $9,616,803. Insiders own 0.12% of the company’s stock.

Several equities research analysts recently issued reports on BDX shares. Morgan Stanley upped their price target on Becton Dickinson and from $250.00 to $261.00 and gave the stock an “equal weight” rating in a report on Tuesday, July 16th. ValuEngine downgraded Becton Dickinson and from a “buy” rating to a “hold” rating in a report on Thursday, August 1st. Wells Fargo & Co upped their price target on Becton Dickinson and from $270.00 to $290.00 and gave the stock an “outperform” rating in a report on Friday, September 6th. Finally, Piper Jaffray Companies decreased their price target on Becton Dickinson and from $267.00 to $266.00 and set an “overweight” rating for the company in a report on Tuesday, August 6th. Five equities research analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $266.55.

About Becton Dickinson and

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral IV and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, IV fluids, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps and dedicated disposables, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems.

Recommended Story: High-Yield Dividend Stocks

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton Dickinson and Co (NYSE:BDX).

Institutional Ownership by Quarter for Becton Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Metropolitan Life Insurance Co NY Acquires 9,443 Shares of ZIOPHARM Oncology Inc.
Metropolitan Life Insurance Co NY Acquires 9,443 Shares of ZIOPHARM Oncology Inc.
Metropolitan Life Insurance Co NY Cuts Stock Position in Paylocity Holding Corp
Metropolitan Life Insurance Co NY Cuts Stock Position in Paylocity Holding Corp
Metropolitan Life Insurance Co NY Sells 14,000 Shares of Washington Prime Group Inc
Metropolitan Life Insurance Co NY Sells 14,000 Shares of Washington Prime Group Inc
Metropolitan Life Insurance Co NY Has $239,000 Stock Holdings in Trupanion Inc
Metropolitan Life Insurance Co NY Has $239,000 Stock Holdings in Trupanion Inc
Metropolitan Life Insurance Co NY Raises Holdings in Focus Financial Partners Inc
Metropolitan Life Insurance Co NY Raises Holdings in Focus Financial Partners Inc
NanoString Technologies Inc  Shares Purchased by Metropolitan Life Insurance Co NY
NanoString Technologies Inc Shares Purchased by Metropolitan Life Insurance Co NY


© 2006-2019 Ticker Report